Jennison Associates
CCCC icon

Jennison Associates’s C4 Therapeutics CCCC Stock Holding History

Jennison Associates’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-27,001
Closed -$869K – 642
2021
Q4 		$869K Sell
27,001
-458,312
-94% -$18.1M ﹤0.01% 638
2021
Q3 		$21.7M Sell
485,313
-2,862
-0.6% -$123K 0.01% 351
2021
Q2 		$18.5M Sell
488,175
-2,973
-0.6% -$106K 0.01% 378
2021
Q1 		$18.2M Buy
491,148
+317,796
+183% +$12.6M 0.01% 367
2020
Q4 		$5.74M Buy
+173,352
New +$5.03M ﹤0.01% 448

Other funds holding CCCC

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Jennison Associates's CCCC Position: Q1 2022 in Review

Jennison Associates sold out of C4 Therapeutics (CCCC) in Q1 2022, closing a stake of 27,001 shares — an estimated $869K sold.

Jennison Associates first reported a position in CCCC in Q4 2020 and held it in 5 quarters. The position peaked at $21.7M in Q3 2021. 125 funds tracked by Wall St. Rank hold CCCC as of Q1 2022.

  • Jennison Associates reported no remaining C4 Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Jennison Associates sold 27,001 C4 Therapeutics shares in Q1 2022, an estimated $869K.
  • Jennison Associates first reported a position in C4 Therapeutics in Q4 2020 and held it in 5 quarters.
  • Jennison Associates's C4 Therapeutics position peaked at $21.7M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.